ERBB2 and neoplasm: However, application of this strategy for the labeling of anti-HER2 DARPin G3 resulted in elevated hepatobiliary excretion of the conjugate, causing decreased tumor uptake and a high activity level in the contents of the gastrointestinal tract [11].